Cyclerion Therapeutics, Inc.
CYCN
$2.95
-$0.20-6.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -69.03% | -88.47% | -93.78% | -96.61% | -97.05% |
| Gross Profit | 682.89% | 308.01% | 105.28% | 96.61% | 96.98% |
| SG&A Expenses | -26.83% | -35.88% | -39.59% | -36.84% | -44.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.55% | -41.65% | -50.28% | -46.80% | -69.26% |
| Operating Income | 56.60% | 62.39% | 51.85% | 46.80% | 68.89% |
| Income Before Tax | 73.11% | 75.72% | 65.30% | 23.72% | 56.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 73.11% | 75.72% | 65.30% | 23.72% | 56.74% |
| Earnings from Discontinued Operations | -- | -- | -100.00% | 189.07% | 187.03% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,075.84% | 41.92% | 51.03% | 110.43% | 100.39% |
| EBIT | 56.60% | 62.39% | 51.85% | 46.80% | 68.89% |
| EBITDA | -- | -- | 85.49% | 68.23% | 75.35% |
| EPS Basic | -2,670.24% | 53.32% | 59.37% | 109.59% | 99.76% |
| Normalized Basic EPS | 63.03% | 69.38% | 60.47% | 54.02% | 72.97% |
| EPS Diluted | -2,687.14% | 53.05% | 59.23% | 109.56% | 99.76% |
| Normalized Diluted EPS | 63.03% | 69.38% | 60.47% | 54.02% | 72.97% |
| Average Basic Shares Outstanding | 6.13% | 9.11% | 8.85% | 11.04% | 9.81% |
| Average Diluted Shares Outstanding | 6.13% | 9.11% | 8.85% | 11.04% | 9.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |